在2型糖尿病中,GLP1R和OCT1变体调节了塞马格卢提德和甲福林的反应
Ivan Tourtourikov1,2, Maria Kalinkova3, Peter Ivanov4
1Department of Chemistry and Biochemistry, Medical Faculty, Medical University.
Pharmacogenetics and genomics
|September 25, 2025
概括
在2型糖尿病患者中,相比于甲福明,塞马格卢提德在短期内显示出优异的减肥效果. 需要进一步的研究来验证与代谢变化的遗传关联.
科学领域:
- 药物基因组学 药物基因组学
- 代谢疾病 代谢疾病
- 临床研究 临床研究
背景情况:
- 遗传联盟已经将SLC22A1,SLC47A1和GLP1R变异与抗糖尿病反应联系起来.
- 现实世界数据有限,可以在较小的患者队伍中证实这些遗传关联.
研究的目的:
- 调查SLC22A1,SLC47A1和GLP1R中常见的多态性是否会影响可测量的3个月代谢变化.
- 为了比较延长释放甲福明 (XR) 和口服赛马格卢提德在患有2型糖尿病的成年人中的疗效.
主要方法:
- 27名2型糖尿病的保加利亚成年人接受了三个月的梅特福林XR或口服赛马格卢提德治疗.
- 桑格测序用于识别SLC22A1 rs628031,SLC47A1 rs2252281和GLP1R rs6923761的特定基因型.
- 主要终点包括体重和糖化血红蛋白 (HbA1c) 的变化;统计分析评估了基因型和治疗效果.
主要成果:
- 与甲福明 (-1.6 公斤和 -0.3 公斤/m2) 相比,塞马格卢丁导致体重减轻 (-6.5 公斤) 和BMI 减轻 (-2.0 公斤/m2) 显著增加.
- 探索性分析揭示了OCT1rs34130495基因型和高密度脂蛋白 (HDL) 变化在甲胺使用者 (q=0.063) 之间存在潜在的关联.
- GLP1R rs6923761 显示,随着塞马格卢提德的使用,体重和BMI变化的趋势不显著.
结论:
- 在这个队列中,对于短期减肥,塞马格卢提德比甲胺更有效.
- 观察到OCT1 rs34130495和HDL之间的关联需要进一步调查和复制.
- 这些发现支持临床实践中基因型导向治疗策略的潜力.
相关概念视频
Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
525
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K


